Save to Existing Project
Save to a New Project
Yeda R&D Co. Ltd
Abstract ID: 1621
Angiogenesis, the growth of new blood vessels from pre-existing vasculature, has an essential role in development, reproduction and repair. Pathological angiogenesis is a common theme in a broad...
Angiogenesis, the growth of new blood vessels from pre-existing vasculature, has an essential role in development, reproduction and repair. Pathological angiogenesis is a common theme in a broad range of diseases such as cancer, autoimmune diseases, age-related macular degeneration and atherosclerosis. The global market for angiogenesis stimulators and inhibitors is forecast to reach ~US $50 billion by the year 2015.
Most of the currently marketed angiogenesis regulators, such as Avastin, typically display modest efficacy and therefore further highlight the great need for the development of novel therapeutics.
Using a high-throughput genetic screen for vascular defects in zebrafish, researchers at the Weizmann Institute of Science have identified a genetic mutation that leads to excessive angiogenesis. The mutated gene is responsible for the assembly of ApoB-containing lipoproteins such as LDL, otherwise known as the ?bad? cholesterol. The group has found that low levels of LDL promote the formation of new blood vessels by directly interacting with the VEGF pathway. The outlined technology offers methods to modulate the levels of ApoB in order to stimulate, or inhibit angiogenesis, dependent on the therapeutic strategy. For example, inhibition of angiogenesis by increasing ApoB levels may repress tumour growth and attenuate its metastatic potential. In another application of this technology, increased circulating levels of ApoB can serve as a biomarker for the overproduction of blood vessels, thus enabling early diagnosis of pathogenic states in angiogenesis-dependent diseases.
The current technology presents a novel method to treat angiogenesis-related disorders by modulating apolipoprotein B (ApoB).
Please enquire quoting reference no. 1621 regarding licensing or codevelopment partnerships.
Last Updated May 2015